DOI: 10.1186/s13550-018-0374-8Pages: 1-11

I-124 codrituzumab imaging and biodistribution in patients with hepatocellular carcinoma

1. Memorial Sloan Kettering Cancer Center, Department of Radiology

2. Memorial Sloan Kettering Cancer Center, Department of Medical Physics

3. Stony Brook University Hospital, Department of Psychiatry and Behavioral Science

4. Stony Brook University Hospital, Department of Radiology

5. Chugai Pharmaceutical Co., Ltd.

6. Memorial Sloan Kettering Cancer Center, Department of Medicine

Correspondence to:
Jorge A. Carrasquillo
Tel: 212-639-2459
Email: carrasj1@mskcc.org

Close

Abstract

Background

I-124 codrituzumab (aka GC33), an antibody directed at Glypican 3, was evaluated in patients with hepatocellular carcinoma (HCC). Fourteen patients with HCC underwent baseline imaging with I-124 codrituzumab (~ 185 MBq, 10 mg). Seven of these patients undergoing sorafenib/immunotherapy with 2.5 or 5 mg/kg of cold codrituzumab had repeat imaging, with co-infusion of I-124 codrituzumab, as part of their immunotherapy treatment. Three patients who progressed while on sorafenib/immunotherapy were re-imaged after a 4-week washout period to assess for the presence of antigen. Serial positron emission tomography (PET) imaging and pharmacokinetics were performed following I-124 codrituzumab. An ELISA assay was used to determine “cold” codrituzumab serum pharmacokinetics and compare it to that of I-124 codrituzumab. Correlation of imaging results was performed with IHC. Short-term safety assessment was also evaluated.

Results

Thirteen patients had tumor localization on baseline I-124 codrituzumab; heterogeneity in tumor uptake was noted. In three patients undergoing repeat imaging while on immunotherapy/sorafenib, evidence of decreased I-124 codrituzumab uptake was noted. All three patients who underwent imaging after progression while on immunotherapy continued to have I-124 codrituzumab tumor uptake. Pharmacokinetics of I-124 codrituzumab was similar to that of other intact IgG. No significant adverse events were observed related to the I-124 codrituzumab.

Conclusions

I-124 codrituzumab detected tumor localization in most patients with HCC. Pharmacokinetics was similar to that of other intact iodinated humanized IgG. No visible cross-reactivity with normal organs was observed.

This article is freely available, click here to access the full text/PDF

  • Accepted: Feb 22, 2018
  • Online: Mar 5, 2018

Article Tools

eanm
EJNMMI Ad